Leflunomida Pentafarma (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, a key step in the synthesis of pyrimidine nucleotides. By limiting pyrimidine production, it reduces the proliferation of activated lymphocytes, thereby dampening the immune response that drives inflammatory arthritis.

The dosage of Leflunomida Pentafarma is determined by the prescribing physician based on the individual’s clinical condition, disease severity, and response to therapy. The prescriber will set the appropriate dose and schedule according to current medical guidelines.

Leflunomide is contraindicated in pregnancy because of known teratogenic risk, and women of child‑bearing potential must use effective contraception. Safety during breastfeeding has not been established, so the drug should be avoided unless the benefits clearly outweigh the potential risks.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Leflunomide is an oral synthetic DMARD that offers a convenient dosing schedule compared with injectable biologics. It has a distinct mechanism—blocking pyrimidine synthesis—whereas methotrexate inhibits folate metabolism. Choice of therapy depends on disease severity, patient preference, and safety considerations.

Leflunomida Pentafarma should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and extreme heat to maintain its stability and potency.

The medication is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water and follow the dosing schedule provided by the healthcare professional.

Serious adverse events include severe liver injury, bone‑marrow suppression leading to anemia or neutropenia, and rare pulmonary toxicity such as interstitial lung disease. Patients should be monitored regularly for liver enzymes, blood counts, and respiratory symptoms.

Leflunomide is contraindicated in patients with pre‑existing severe liver disease, active infections, or known hypersensitivity to the drug. It should also be avoided in pregnant women and in individuals who cannot use reliable contraception during treatment.